Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL100726 | 1.00 | — | — | |
| SCHEMBL3911252 | 1.00 | ALDH1A1 (0.44) | ALDH1A1GAAACHETSHR | |
| SCHEMBL27056299 | 1.00 | ALDH1A1 (0.44) | ALDH1A1GAAACHETSHR | |
| SCHEMBL25259503 | 1.00 | ALDH1A1 (0.44) | ALDH1A1GAAACHETSHR | |
| SCHEMBL922730 | 1.00 | — | — | |
| SCHEMBL25269862 | 1.00 | ALDH1A1 (0.44) | ALDH1A1GAAACHETSHR | |
| SCHEMBL3912551 | 1.00 | ALDH1A1 (0.44) | ALDH1A1GAAACHETSHR | |
| SCHEMBL259495 | 0.97 | — | — | |
| SCHEMBL8171 | 0.87 | — | — | |
| SCHEMBL30810268 | 0.85 | ALDH1A1 (0.35) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4561585-A1 | IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS FOR USE IN THE TREATMENT, INHIBITION OF PROGRESSION, AND PREVENTION OF ECTOPIC CALCIFICATION | Sanifit Therapeutics S.A. (ES) | 2025-06-04 | — | — | EP | disclosed |
| CN-119855595-A | IP4-4,6 substituted derivative compounds for treating ectopic calcification, inhibiting progression and preventing ectopic calcification | 萨尼菲特治疗有限公司 | 2025-04-18 | — | — | CN | disclosed |
| US-20240109924-A1 | IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS | VIFOR (INTERNATIONAL) LTD. (CH) | 2024-04-04 | — | — | US | disclosed |
| WO-2024023359-A1 | IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS FOR USE IN THE TREATMENT, INHIBITION OF PROGRESSION, AND PREVENTION OF ECTOPIC CALCIFICATION | SANIFIT THERAPEUTICS, S.A. (ES) | 2024-02-01 | — | — | WO | disclosed |
| WO-2023246074-A1 | CATIONIC LIPID COMPOUND FOR NUCLEIC ACID DELIVERY, COMPOSITION AND USE | 深圳瑞吉生物科技有限公司 | 2023-12-28 | — | — | WO | disclosed |
| EP-4284809-A1 | IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS | Sanifit Therapeutics S.A. (ES) | 2023-12-06 | — | — | EP | disclosed |
| CN-116745304-A | IP4-4,6 substituted derivative compounds | 萨尼菲特治疗有限公司 | 2023-09-12 | — | — | CN | disclosed |
| WO-2022162206-A1 | IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS | SANIFIT THERAPEUTICS, S.A. (ES) | 2022-08-04 | — | — | WO | disclosed |
| EP-4036097-A1 | IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS | Sanifit Therapeutics S.A. (ES) | 2022-08-03 | — | — | EP | disclosed |
| EP-2376432-B1 | NOVEL EICOSANOID DERIVATIVES | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (MDC) (DE) | 2017-04-12 | — | — | EP | disclosed |
| EP-0504812-B1 | Aromatic compounds, their production processes and their compositions for the control of insect pests | SUMITOMO CHEMICAL CO (JP) | 1995-09-06 | — | — | EP | disclosed |
| US-5302619-A | Aromatic compounds, their production processes and their compositions for the control of insect pests | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1994-04-12 | — | — | US | disclosed |
| US-5262441-A | APPLYING INSECTICIDE TO INSECT OR LOCUS WHERE INSECT PROPAGATES | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1993-11-16 | — | — | US | disclosed |
| EP-0504812-A2 | Aromatic compounds, their production processes and their compositions for the control of insect pests | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1992-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109924-A1 | IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS | IPO4, TPX2, IPO9 | ALDH1A1 4700/4885GAA 3541/4885ACHE 2448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.